Historical Review of Pertussis and the Classical Vaccine
|
|
- Buddy Blair
- 8 years ago
- Views:
Transcription
1 5259 Historical Review of Pertussis and the Classical Vaccine James D. Cherry Department ofpediatrics, UCLA School ofmedicine, UCLA Children's Hospital, and UCLA Center for Vaccine Research, Los Angeles. California Pertussis is an epidemic disease caused by Bordetella pertussis and also to a lesser extent by Bordetella parapertussis. Classical illness lasts 4-8 weeks and is characterized by paroxysms of coughing with posttussive vomiting and whooping; however, 47.4% of primary infections last 4 weeks or less. Whole cell pertussis vaccines are generally highly efficacious. All whole cell vaccines are reactogenic, causing fever and local reactions in many vaccinees. In the past, these vaccines were thought to cause infant deaths and brain damage. However, several large epidemiologic studies indicate that whole cell vaccines do not cause infant deaths or neurologic disease. Recent studies indicate that neither immunization nor infection give long-term immunity. As a result, B. pertussis infections are endemic in adult populations. The future control of B. pertussis will require immunization schedules with new acellular vaccines that include booster doses in older children and adults. Pertussis (whooping cough) has been and remains an endemic disease with significant morbidity and mortality [1-4]. At present, more than 355,000 deaths are caused by pertussis annually, mainly in unimmunized children in developing countries [4]. The disease pertussis and its cause are reviewed along with development and use of classical vaccines and past and present epidemiology of Bordetella pertussis infection, which is the main cause of the disease. Pertussis History. Pertussis (whooping cough) was first recognized in the Middle Ages [5]. It was described as "the kink" (a Scottish term synonymous with fit or paroxysm) and "kindhoest" (a teutonic word meaning child's cough). The first epidemic, described by Guillaume de Baillou, occurred in Paris in 1578 (cited in [6]). In 1906, Bordet and Gengou [7] reported the isolation ofthe causative organism (B. pertussis). Throughout this century, endemic and epidemic disease caused by B. pertussis has occurred in all populations with unimmunized children [1-3, 8]. Causative organisms. Pertussis is caused by gram-negative pleomorphic bacilli of the genus Bordetella [1]. The predominant cause is B. pertussis, but B. parapertussis also causes typical pertussis [9]. B. bronchiseptica, an animal pathogen, can also cause rare instances of illness with chronic cough in humans. Recently, in Germany, during a 4-year laboratory study in conjunctionwith a vaccine efficacytrial, 6% ofculturepositive cases of pertussis were caused by B. parapertussis Financial support: Lederle-Praxis Biologicals; NIH (AJ-15124). Reprints or correspondence: Prof. James D. Cherry, Dept. of Pediatrics, UCLA School of Medicine, MDCC, Le Conte Ave., Los Angeles, CA The Journal of Infectious Diseases 1996; 174(8uppl 3): by The University of Chicago. All rights reserved. 0022~1899/96/74S3-000 I$ (unpublished data). It is often stated that Chlamydia trachomatis and certain adenoviruses can cause clinical pertussis. However, it is my view that illnesses caused by these agents are sufficiently different from those caused by B. pertussis so that clinical confusion should not occur. Laboratory diagnosis. The standard laboratory method for the diagnosis ofb. pertussis infection is culture ofthe organism from a nasopharyngeal swab. It is a common beliefthat culture has low sensitivity, but when specimens are collected early in a typical case and transport and laboratory techniques are done correctly, the isolation rate is ~80% [10]. Isolation rates are worse ifspecimens are collected late (cough lasts > 2 weeks), if antibiotics have been administered, if subjects were previously vaccinated, or if they are previously infected adults. Infection with B. pertussis can also be diagnosed serologically by the demonstration of a 4-fold increase in agglutinin titer or a significant increase in IgA or IgG antibody determined by ELISA to B. pertussis antigens when acute- and convalescent-phase serum specimens are compared [3]. In epidemiologic studies, B. pertussis infections can also be diagnosed by significantly high single-agglutinin titers or ELISA antibody values [11]. The B. pertussis antigens used in ELISA for diagnosis are pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (69-kDa outer membrane protein), and fimbriae. B. parapertussis has FHA and an outer membrane protein similar to that of B. pertussis, and therefore infection with B. parapertussis will often result in a rise in antibody levels to these two B. pertussis antigens (unpublished data). Recently, the polymerase chain reaction (PCR) has been used as an additional laboratory method for the identification ofb. pertussis in nasopharyngeal specimens. In a study by my group, PCR increased the identification of subjects with B. pertussis infections by almost 4-fold [12]. Additional identified cases included persons with prior antibiotic treatment, less severe illnesses, and delayed specimen collection. Extreme care in the laboratory with appropriate controls is required to avoid contamination and false-positive results.
2 8260 Cherry lid 1996; 174 (Suppl 3) Also extremely useful in the diagnosis ofb. pertussis infection is the occurrence of absolute lymphocytosis [1]. Such lymphocytosis is caused by PT (also called lymphocytosispromoting factor) and occurs during primary infections in persons without antibody to PT. A lymphocyte count of 10,000 cells/mnr' in a child with a cough or an infant with apnea virtually always indicates B. pertussis infection. Pathogenesis ofb. pertussis infection. The transmission of infection from one person to another is presumed to be airborne from the cough of an infected person to the respiratory epithelium ofthe new host, where the organisms attach to the cilia ofepithelial cells [13]. Important adhesions for attachment are PT, FHA, and pertactin. Fimbriae may also playa role in continued attachment. After attachment, host immune-effector cell function and bacterial clearance is disrupted by adenylate cyclase toxin and PT. Local tissue damage, which presumably is the cause of symptoms, is likely to result from tracheal cytotoxin and perhaps dermonecrotic toxin. Pertussis is a unique illness in that systemic manifestations rarely occur [1]. Convulsions and encephalopathy are most likely caused by anoxia resulting from respiratory damage. It is possible, however, that they result from systemic toxin. In infection, there is both lymphocytosis and hyperinsulinism caused by dissemination of PT. Therefore, it is possible that both seizures and encephalopathy could result from hypoglycemia due to PT; however, at present, no data support this hypothesis. In 1979, it was suggested that pertussis was a disease caused by PT alone [14]. This idea is still prevalent but is not credible because an illness identical to that caused by B. pertussis is caused by B. parapertussis, and the latter organism does not liberate PT [9]. Clinical illness from B. pertussis infection. Classical pertussis follows an incubation period of 6-20 days. The onset of most cases is 7-10 days after exposure [1]. It is an illness of three stages (catarrhal, paroxysmal, and convalescent) and lasts 4-8 weeks and occasionally longer. Initially, illness starts like a cold with coryza and mild cough. The cough becomes more prominent with paroxysms, posttussive vomiting, and posttussive whooping. Typically there is no fever, no signs or symptoms of systemic illness, and no pharyngitis. Lymphocytosis occurs. These manifestations occur during primary infection in previously unimmunized children. Atypical illnesses occur in both children and adults who have previously been vaccinated or infected [1, 10, 11]. In addition, neonates and young infants with primary infections may present with apnea and seizures without apparent paroxysmal cough [15]. The usual clinical manifestations of B. pertussis infection in adults seem to differ in those who were vaccinated in childhood and in those whose initial exposure to the organism in childhood was by infection [11, 16]. In all adults, the main manifestation is persistent paroxysmal cough, which is largely unresponsive to conventional treatments. The correct diagnosis is rare; the most common incorrect diagnosis is bronchitis. Reinfections in adults not immunized during childhood are more likely to be typical of classical pertussis (with whooping). Recently it was noted that a significant number of primary infections with B. pertussis in unimmunized children do not result in classical pertussis. In a study in Germany, physicians were encouraged to send in cultures for B. pertussis in all respiratory illnesses with cough, regardless ofwhether the illnesses were thought to be pertussis [10]. In this study, 47.4% of 247 children with culture-confirmed B. pertussis infections had illnesses that lasted ~4 weeks; in 25.5%, the illnesses persisted ~3 weeks. Vaccines History. After the isolation of B. pertussis in 1906, the possibility of vaccine development was considered because pertussis was such a devastating disease [1]. In 1933, Madsen [17] reported some degree of protection in vaccinees who received a vaccine composed of suspended organisms (10 X 10 9 ; ml) in phenolyzed saline. In the 1930s, pertussis vaccines were used both to prevent pertussis and for treatment. During this period, many different types of vaccines were experimented with, and some were found to be efficacious [18]. Types of vaccines investigated were whole cell preparations, which were washed or unwashed, mixed vaccines that also contained other bacteria of the upper respiratory tract flora, fractionated vaccines (extracted, crude acellular products), "detoxified vaccines," and vaccines enriched with "toxic factors." In early studies, it was found that to obtain a good antibody response and protection after immunization, the total bacterial count in the vaccine needed to be high. However, because of toxicity, the number of organisms in a single dose was limited [1]. Studies with whole cell vaccines in the United States (US) in the late 1930s and early 1940s revealed marked differences in efficacy; however, in four large studies (>500 children), the efficacies were 91.5%, 87.7%, 91.5%, and 53% [18]. Large trials in the United Kingdom (UK) after World War II also demonstrated marked differences in efficacy between vaccines [1, 2]. In 1947, Kendrick et al. [19] described the mouse intracerebral challenge protection test for vaccine standardization. In the UK trials, a three-dose series of vaccines containing 4 protective units (as defined by Kendrick et al.) had an efficacy of 80% against home exposure [20]. Conventional whole cell vaccines. Whole cell vaccines are manufactured in many countries. Although their basic preparation procedures are similar, the vaccines frequently elicit markedly different immune responses to various B. pertussis antigens. In general, B. pertussis is grown in bulk culture, harvested, concentrated by centrifugation, and suspended in a buffered saline solution [1]. Concentrated bacteria are killed and partially detoxified by heat or a chemical agent or by a combination of these methods. The pertussis component is
3 JID 1996; 174 (Suppl 3) Pertussis and the Classical Vaccine S261 combined with diphtheria and tetanus toxoids, which have been adsorbed onto an aluminum adjuvant. Immunization schedules. There are many different immunization schedules in use throughout the world, but few were developed on the basis of scientific efficacy information [1]. However, it is apparent that even scientifically less-than-optimal schedules are effective. Often vaccination schedules have been determined on the basis of perceived and real reactogenicity. Immunogenicity data indicate that a primary series should consist ofthree doses and that booster doses are necessary at ages 2 and 4-6 years. The apparent success of schedules that include only three doses in the first year oflife can be explained by the failure in older children of recognition ofvaccine-modified pertussis (see discussion on epidemiology) [2]. There is a reluctance to give booster doses in many countries because of excessive local reactions at the site of injection. Such reactions are at variance with postbooster reactions in the US, where a five-dose schedule is routine. A major reason for this difference is that the content of diphtheria toxoid in vaccines used in many countries other than the US is more than necessary [21]. The local reactions are, to a large extent, immunologic because of the diphtheria toxoid in the vaccine and not the pertussis component. Real and perceived vaccine reactions. All whole cell pertussis vaccines contain both endotoxin and other active toxins, so it is not surprising that reactions occur. In addition, adverse events, such as an Arthus reaction, can be mediated immunologically after a booster dose. Reactions can be caused by the vaccine or perceived from the temporal association between an immunization and an unusual event. Transient local and systemic reactions. Although reactions have been noted in association with pertussis immunization since the first vaccines were tested >60 years ago, only recently were quantitative controlled studies done [1, 2]. Between 1978 and 1979, reactions in 15,752 diphtheria-tetanus toxoid (DT) pertussis (DTP) recipients were compared with those in 784 DT recipients (table 1) [22]. Nine of 10 reactions listed in table 1 occurred significantly more frequently in DTP vaccine recipients than in DT vaccinees. Local reactions were generally more frequent with increasing doses, whereas systemic reactions, with the exception of fever, were less frequent with increasing doses. The occurrence of fever correlated directly with the vaccine endotoxin content [23]. Reactions varied with different vaccine production lots. In the same study, 9 children experienced hypotonic-hyporesponsive episodes, and 9 children had seizures [22]. In more recent investigations, my group has done studies to determine the cause ofhypotonic-hyporesponsive episodes, seizures, and persistent crying [24]. In these studies, persistent crying was associated with painful local reactions, seizures were characteristic of febrile seizures, and fever most likely resulted from vaccine endotoxin. We found no evidence that PT plays a role in hypotonic-hyporesponsive episodes or seizures. Table 1. Less serious reactions following 15,752 DTP and 784 DT immunizations. Reaction DTP group DT group P Local Redness 5891 (37.4) 60 (7.6) <.001 Swelling 6411 (40.7) 60 (7.6) <.001 Pain 8018 (50.9) 78 (9.9) <.001 Systemic Fever (38 C) 3605 (46.5) 27 (9.9) <.001 Drowsiness 4962 (31.5) 117 (14.9) <.001 Fretfulness 8412 (53.4) 177 (22.6) <.001 Vomiting 977 (6.2) 20 (2.6) <.001 Anorexia 3292 (20.9) 55 (7.0) <.001 Persistent crying 488 (3.1) 5 (0.7).003 High-pitched, unusual cry 17(0.1) NOTE. Data are no. (%). Modified with permission from [22]. * Fever was evaluated 3 and 6 h after diphtheria-tetanus toxoid-pertussis (DTP) and DT immunizations in 7753 and 292 children, respectively. Neurologic illness and death temporally associated with DTP immunization. The first and second doses of DTP are frequently administered at the age of the peak occurrence of the sudden infant death syndrome (SIDS). Therefore, it is not surprising that many SIDS cases occur after immunization in temporal association. However, several excellent controlled studies indicate there is no causative role ofpertussis vaccine in SIDS [1, 3]. Neurologic events after pertussis immunization have been recognized since the early days ofpertussis immunization [1, 3]. These events were initially called "pertussis vaccine encephalitis" and more recently' 'pertussis vaccine encephalopathy." However, when cases of so-called vaccine encephalopathy are examined, the illnesses are characteristic of the first seizures in infantile epilepsy and not different from illnesses in nonvaccinated children of similar ages [1]. In recent years, five large epidemiologic studies have been done and their results analyzed (with some reanalyzed extensively) [25-29]. From these studies, it has been concluded that "pertussis vaccine encephalopathy is a myth" [30]. Pertussis vaccine causes the first febrile seizure in prone children and accelerates the occurrence of the first seizure of infantile epilepsy. This latter event is most clearly demonstrated in infantile spasms [31], but other infantile epilepsies also result from preexisting but unrecognized brain damage and can be accelerated by pertussis immunization. Vaccine efficacy. Whole cell pertussis vaccines in use today are clearly efficacious despite the use of less-than-optimal immunization schedules in many countries. Efficacy can be demonstrated in several ways. The most graphic is the resurgence of epidemic pertussis in a country after discontinuation or marked reduction in vaccine use. Epidemic pertussis was relatively controlled in the UK, Japan, and Sweden in the early 1970s [1]. In the UK and Japan, immunization was markedly disrupted, and epidemic disease occurred. In both countries,
4 S262 Cherry JID 1996; 174 (Supp1 3) pertussis was subsequently brought under control with the renewed use of pertussis vaccines. In contrast with the UK and Japan, pertussis immunization was discontinued in Sweden in 1979 and, despite persistent epidemic disease with both morbidity and mortality, immunization was not reintroduced. The efficacy of whole cell pertussis vaccines has also been demonstrated in numerous household contact studies. Efficacy varies by case definition: The most recent US data indicate efficacies between 59% and 97%, depending upon the case definition [32]. In Germany, the efficacy of the whole cell vaccine (produced by Behringwerke, Marburg, Germany) was calculated to be 97.6% (95% confidence interval, ) by Schmitt et al. [33]. Epidemiology In the prevaccine era and in populations where immunization is not done, pertussis is an epidemic disease with cycles every 2-5 years [1-3]. Fine and Clarkson [34] noted that this cycle did not change, despite a reduction in total cases by immunization. This indicates that immunization controls disease but does not control the prevalence of the organism in the population. From September 1986 to February 1989, my group studied cough illnesses in UCLA students [11]. We found that 26% of those with an illness of 6 days had B. pertussis infections, but none were recognized by their physicians. Since we demonstrated B. pertussis throughout the 2.5-year period, we suggested that B. pertussis infections are endemic in adults and cause the epidemic cycles that predominantly involve unvaccinated children. Since there has been effective routine immunization in the US for > 30 years, these cases in UCLA students occurred in previously vaccinated persons. The prevailing opinion is that vaccine immunity is relatively short-lived, whereas immunity following infection is lifelong. Studies by UCLA researchers suggest this opinion is wrong. Knowing that IgA antibodies to pertussis antigens (PT, FHA, and pertactin) usually result from infection and not vaccination, their prevalence in young German and American men ofsimilar ages was studied [35]. In Germany, routine childhood immunization was not done during the 1970s and 1980s and pertussis was epidemic. To our surprise, the rate and mean values of IgA antibodies in the two populations were similar, suggesting similar adult infection rates. In another study in Germany, B. pertussis infections were common in adults (133/100,000 population) and often occurred in those with a history of childhood pertussis [16]. These data indicate that in populations in which pertussis is controlled by immunization and in populations in which pertussis is epidemic, endemic disease occurs in adults. This endemic disease is responsible for the cyclic disease observed in unvaccinated children. Summary and Conclusions Whole cell pertussis vaccines have been highly successful in controlling epidemic pertussis. Their use, however, has not curtailed the circulation of B. pertussis in the population. In addition, whole cell pertussis vaccines are safe but cause considerable short-term discomfort. In the near future, if the circulation of B. pertussis and pertussis disease is to be controlled, programs involving booster immunizations of older children and adults will be needed. Adult booster immunizations with present whole cell vaccines are not a practical consideration because of reactogenicity. However, endotoxin-free acellular pertussis vaccines should be acceptable for adult use. Immunization programs that include older children and adults may enable the control ofb. pertussis circulation as well as pertussis disease. References 1. Cherry JD, Brunell PA, Golden GS, Darzon DT. Report of the task force on pertussis and pertussis immunization Pediatrics 1988; 81(suppl): Cherry JD. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. CUff Probl Pediatr 1984; 14: Hodder SL, Mortimer EA Jr. Epidemiology of pertussis and reactions to pertussis vaccine. Epidemiol Rev 1992; 14: Strebel P, Wharton M, Cochi S. Impact of pertussis vaccination on the burden of acute respiratory illness (ARI) among children in developing countries [abstracts]. In: Program of 122nd annual meeting and exhibition of the American Public Health Association (Washington, DC), 1994: Holmes WHo Whooping cough or pertussis. In: Holmes WH, ed. Bacillary and rickettsial infections: acute and chronic, black death to white plague. New York: Macmillan, 1940: Linnemann CC Jr. Host-parasite interactions in pertussis. In: Manclark CR, Hill JC, eds. International Symposium on Pertussis. Washington, DC: Government Printing Office, US Department ofhealth, Education and Welfare (NIH) , 1979: Bordet J, Gengou U. Le microbe de la coqueluche. Ann Inst Pasteur 1906; 20: Cherry JD, Baraff LJ, Hewlett E. The past, present, and future of pertussis-the role of adults in epidemiology and future control. West J Med 1989; 150: Heininger U, Stehr K, Schmitt-Grohe S, et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J 1994; 13: Heininger U, Cherry JD, Eckhardt T, Lorenz C, Christenson P, Stehr K. Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany. Pediatr Infect Dis J 1993; 12: Mink C, Cherry JD, Christenson P, et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992; 14: Schlapfer G, Cherry JD, Heininger U, et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatr Infect Dis 1995; 14: Weiss AA, Hewlett EL. Virulence factors of Bordetella pertussis. Annu Rev Microbiol 1986;40: Pittman M. Pertussis toxin: the cause of harmful effects and prolonged immunity of whooping cough. A hypothesis. Rev Infect Dis 1979; 1: Heininger U, Stehr K, Cherry JD. Serious pertussis overlooked in infants. Eur J Pediatr 1992; 151: Schmitt-Grohe S, Cherry JD, Heininger U, Oberall M, Pineda E, Stehr K. Pertussis in German adults. Clin Infect Dis 1995;21:860-6.
5 JlD 1996; 174 (Suppl 3) Pertussis and the Classical Vaccine S Madsen T. Vaccination against whooping cough. JAMA 1933; 101: 187~ Lapin JH. Whooping cough. Springfield, IL: CC Thomas, Kendrick PL, Eldering G, Dixon MK, Misner J. Mouse protection tests in the study of pertussis vaccines. Am J Public Health 1947;37: DHSS Joint Committee on Vaccination and Immunization. Whooping cough vaccination: review ofthe evidence on whooping cough vaccination. London: Her Majesty's Stationery Office, Cherry JD. Strategies for pediatric vaccines: conventional and molecular approaches in strategies for pediatric vaccines. Report of the 104th Ross Conference on Pediatric Research. Columbus, OH: Ross Products Division, Abbott Laboratories, 1994: Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68: Baraff LJ, Manc1ark CR, Cherry JD, Christenson P, Marcy SM. Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr Infect Dis J 1989; 8: Blumberg DA, Lews K, Mink C, Christenson P, Chatfield P, Cherry JD. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying. Pediatrics 1993;91: Alderslade R, Bellman M, Rawson N, Ross EM, Miller DL. The National Childhood Encephalopathy Study. In: Whooping cough: reports from the Committee and Safety of Medicine and the Joint Committee on Vaccination and Immunization. London: DHSS, 1981: Shields WD, Nielson C, Buch D, et ai. Relationship ofpertussis immunization to the onset of neurologic disorders: a retrospective epidemiologic study. J Pediatr 1988; 113: Griffin MR, Ray WS, Mortimer EA, Fenichel GM, Schaffner W. Risk of seizures and encephalopathy after immunization with the diphtheriatetanus-pertussis vaccine. JAMA 1990;263: Walker AM, Jick H, Parera DR, Knauss TA, Thompson RS. Neurologic events following diphtheria-tetanus-pertussis immunization. Pediatrics 1988; 81: Gale JL, Thapa PB, Wassilak SG, Bobo JK, Mendelman PM, Foy HM. Risk ofserious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine. A population-based case-control study. JAMA 1994;271: Cherry JD. "Pertussis vaccine encephalopathy": it is time to recognize it as the myth that it is [editorial]. JAMA 1990;263: Bellman MH, Ross EM, Miller DL. Infantile spasms and pertussis immunization. Lancet 1983; 1: Onorato 1M, Wassilak SG, Meade BD. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA 1992;20: Schmitt HJ, Schuind A, Knuf M, et ai. Acellular pertussis vaccines: the rationale for an efficacy trial in Germany. J Infect Dis 1996;174(suppl 3):S Fine PEM, Clarkson JA. The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet 1982; 1: Cherry JD, Beer T, Chartrand SA, et ai. Comparison of antibody values to Bordetella pertussis antigens in young German and American men. Clin Infect Dis 1995; 20:
Pertussis: Whooping Cough
Pertussis: Whooping Cough By: David Stamps Disease Etiology: Pertussis is caused by the bacteria Bordetella pertussis and Bordetella parapertussis, the latter often resulting in milder symptoms due to
More informationAlberta Health and Wellness Public Health Notifiable Disease Management Guidelines August 2011
August 2011 Pertussis Revision Dates Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive) August 2011 August 2011 December 2005 Case Definition
More informationPertussis BORDETELLA PERTUSSIS PATHOGENESIS CLINICAL FEATURES
Pertussis, or whooping cough, is an acute infectious disease caused by the bacterium Bordetella pertussis. Outbreaks of pertussis were first described in the 16th century, and the organism was first isolated
More informationPerspective. Historical Perspective on Pertussis and Use of Vaccines To Prevent It. 100 years of pertussis (the cough of 100 days) James D.
Historical Perspective on Pertussis and Use of Vaccines To Prevent It 100 years of pertussis (the cough of 100 days) James D. Cherry nlike many other severe epidemic U infectious diseases, pertussis lacks
More informationLinda C. Lambert, PhD Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
Pertussis Vaccine Trials in the 1990s Linda C. Lambert, PhD Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland Target Audience Physicians
More informationPERTUSSIS SURVEILLANCE AND RESPONSE PROTOCOL
PERTUSSIS SURVEILLANCE AND RESPONSE PROTOCOL Public Health Action 1. Educate the public, particularly parents of infants, about the dangers of whooping cough and the advantages of initiating immunization
More informationPertussis. Chapter 15 Pertussis. August 2015. Pertussis. Vaccine introduced in 1952/53 (DTP) and 1996 (DTaP) NOTIFIABLE
Chapter 15 15 Vaccine introduced in 1952/53 (DTP) and 1996 (DTaP) NOTIFIABLE In some circumstances, advice in these guidelines may differ from that in the Summary of Product Characteristics of the vaccines.
More informationFREQUENTLY ASKED QUESTIONS ABOUT PERTUSSIS (WHOOPING COUGH)
FREQUENTLY ASKED QUESTIONS ABOUT PERTUSSIS (WHOOPING COUGH) What is pertussis? General Questions About Pertussis Pertussis, or whooping cough, is a contagious illness that is spread when an infected person
More informationPertussis. Bordetella pertussis. Pathogenesis. Clinical Features
Pertussis, or whooping cough, is an acute infectious disease caused by the bacterium Bordetella pertussis. Outbreaks of pertussis were first described in the th century, and the organism was first isolated
More informationPENNSYLVANIA DEPARTMENT OF HEALTH 2015 PAHAN 307 04-02-ADV Pertussis in Centre County
PENNSYLVANIA DEPARTMENT OF HEALTH 2015 PAHAN 307 04-02-ADV Pertussis in Centre County DATE: 04/02/2015 TO: Health Alert Network FROM: Karen M. Murphy, PhD, RN, Acting Secretary of Health SUBJECT: DISTRIBUTION:
More informationRemove this cover sheet before redistributing and replace it with your own. Please ensure that DPHHS is included on your HAN distribution list.
State of Montana Health Alert Network DPHHS HAN ADVISORY Cover Sheet DATE: May 15, 2012 SUBJECT: Pertussis INSTRUCTIONS: DISTRIBUTE to your local HAN contacts. This HAN is intended for general sharing
More informationPROTOCOL FOR THE MANAGEMENT OF CLOSE CONTACTS OF PERTUSSIS INFECTION
PROTOCOL FOR THE MANAGEMENT OF CLOSE CONTACTS OF PERTUSSIS INFECTION Printed copies must not be considered the definitive version DOCUMENT CONTROL PROTOCOL NO. 1.03 Policy Group Infection Control Committee
More informationWelcome to the California Immunization Coalition Education Hour
Welcome to the California Immunization Coalition Education Hour 1 Pertussis Update: Where Are We and Where Are We Going? 2 . Webinar Objectives Learn about the current epidemiology and trends regarding
More informationParents and Grandparents
Parents and Grandparents Vaccination for parents and grandparents is vital to help protect newborn babies against whooping cough. Protect your baby by being immunised too. To find out more about Boostrix
More informationPertussis Information for GPs and other Health Care Providers on Clinical and Public Health Management. March 2010
Pertussis Information for GPs and other Health Care Providers on Clinical and Public Health Management March 2010 Infectious Agent Bordetella pertussis (a bacterium) Clinical Features Infants and Young
More informationClinical Infectious Diseases Advance Access published October 19, 2014
Clinical Infectious Diseases Advance Access published October 19, 2014 1 Tdap Immunization in Pregnant Women and the Prevention of Pertussis in Young Infants James D. Cherry Department of Pediatrics, David
More informationSummary of the risk management plan (RMP) for Tritanrix HB [Diphtheria, tetanus, pertussis (whole cell) and hepatitis B (rdna) vaccine (adsorbed)]
EMA/14365/2014 Summary of the risk management plan (RMP) for Tritanrix HB [Diphtheria, tetanus, pertussis (whole cell) and hepatitis B (rdna) vaccine (adsorbed)] Overview of disease epidemiology Diphtheria
More informationLaboratory confirmation requires isolation of Bordetella pertussis or detection of B. pertussis nucleic acid, preferably from a nasopharyngeal swab.
Pertussis Epidemiology in New Zealand New Zealand has continued to experience outbreaks of pertussis in recent decades. This is in part due to historically low immunisation rates and in part because immunity
More informationNew Jersey Department of Health Vaccine Preventable Disease Program Pertussis FAQs. Date: January 10, 2013
New Jersey Department of Health Vaccine Preventable Disease Program Pertussis FAQs Date: January 10, 2013 KEY MESSAGES: 1. Pertussis is a very contagious vaccine-preventable disease that can cause serious
More informationAPIC Practice Guidance Committee: Implementation Insights Prevention & Control of Pertussis
1275 K Street, NW, Suite 1000 Washington, DC 20005-4006 Phone: 202/789-1890 Fax: 202/789-1899 apicinfo@apic.org www.apic.org APIC Practice Guidance Committee: Implementation Insights Prevention & Control
More informationBrain damage following whooping cough vaccination - is it time to lay the myth to rest?
Maltese Medical Journal, 998; 0():5 All rights reserved 5 Brain damage following whooping cough vaccination is it time to lay the myth to rest? ~ Victor E Grech*, Ray Busuttil** ABSTRACT: Whooping cough
More informationFactsheet September 2012. Pertussis immunisation for pregnant women. Introduction
Factsheet September 2012 Pertussis immunisation for pregnant women Introduction The routine childhood immunisation programme has been very effective in reducing the overall numbers of cases of pertussis.
More informationI am reaching out to you with some preventative information that you might be interested in sharing with your school community.
Reported cases of pertussis (whooping cough) are on the rise in Colorado and El Paso County. As of October 23, more than 1,000 cases of pertussis have been reported across the state. El Paso County cases
More informationPrevention of Pertussis Among Pregnant & Post Partum Women and Their Infants. Marilyn Michels RN MSN CIC Kathleen Curtis MS RN
Prevention of Pertussis Among Pregnant & Post Partum Women and Their Infants Marilyn Michels RN MSN CIC Kathleen Curtis MS RN Pertussis and Adults Pertussis (whooping cough) a poorly controlled vaccine-preventable
More informationCommunity Health Administration
Community Health Administration 300 North San Antonio Road Santa Barbara, CA 93110-1332 805/681-5439 FAX 805/681-5200 Takashi M. Wada, MD, MPH Director/Health Officer Anne M. Fearon Deputy Director Suzanne
More informationInformation on Measles and Whooping Cough: Vaccination and Disease
Information on Measles and Whooping Cough: Vaccination and Disease Vaccine s Mechanism of Action Vaccines expose the recipient to a small amount of an weakened organism. Through this exposure, the body
More informationVaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for registered healthcare practitioners
Vaccination against pertussis (whooping cough) - the replacement of Repevax with Boostrix -IPV an update for registered healthcare practitioners Questions and Answers May 2014 Health Protection Scotland
More informationTdap booster vaccine for Health Care Workers Frequently Asked Questions for Health Professionals
Tdap booster vaccine for Health Care Workers Frequently Asked Questions for Health Professionals NEW items in 2013 Immunisation Guidelines for Ireland are in RED What is Tdap booster vaccine? Tdap is a
More informationThe clinical studies have been performed in children, adolescents and adults, from 4 years up to 55 years of age.
NAME OF THE MEDICINE TdaP-Booster. Diphtheria, tetanus and pertussis (acellular mono-component) vaccine (adsorbed, reduced antigen content). DESCRIPTION TdaP-Booster is a suspension for injection in pre-filled
More informationHealth Professionals Advice: Azithromycin now fully funded 3 December 2012
Health Professionals Advice: Azithromycin now fully funded 3 December 2012 SITUATION UPDATE The Pertussis epidemic has continued all year, and is expected to continue throughout 2013. Between 1 January
More informationImmunity and how vaccines work
1 Introduction Immunity is the ability of the human body to protect itself from infectious disease. The defence mechanisms of the body are complex and include innate (non-specific, non-adaptive) mechanisms
More informationPertussis: recurrence in this last decade? Denis Piérard Bordetella Reference Laboratory Academisch Ziekenhuis Vrije Universiteit Brussel
Pertussis: recurrence in this last decade? Denis Piérard Bordetella Reference Laboratory Academisch Ziekenhuis Vrije Universiteit Brussel 1 Introduction Pertussis = kinkhoest = whooping cough = coqueluche
More informationAntibody Responses to Bordetella pertussis Antigens and Clinical Correlations in Elderly Community Residents
7 Antibody Responses to Bordetella pertussis Antigens and Clinical Correlations in Elderly Community Residents Sally L. Hodder, 1 James D. Cherry, 2 Edward A. Mortimer, Jr., 1 Amasa B. Ford, 1 Jeffrey
More informationPertussis (whooping cough) immunisation for pregnant women the safest way to protect yourself and your baby
Factsheet September 2012 Pertussis (whooping cough) immunisation for pregnant women the safest way to protect yourself and your baby The routine childhood immunisation programme has been very effective
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Management and post-exposure prophylaxis for suspected cases of pertussis (Whooping Cough)
The Newcastle upon Tyne Hospitals NHS Foundation Trust Management and post-exposure prophylaxis for suspected cases of pertussis (Whooping Cough) Version No.: 5.0 Effective From: 2 May 2013 Expiry Date:
More informationChapter 3. Immunity and how vaccines work
Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity
More informationIs your family at risk for pertussis?
Is your family at risk for pertussis? Help protect your family against a serious disease and talk to your health-care professional about adult and adolescent immunization with Adacel vaccine. Please click
More informationEvaluation of Pertussis Treatment with Erythromycin Ethylsuccinate and Stearate According to Age
Evaluation of Pertussis Treatment with Erythromycin Ethylsuccinate and Stearate According to Age Hirokazu KAWAI, Tatsuo AOYAMA, Akira GOTO, Hidehito IWAI and Yuji MURASE Department of Pediatrics, School
More informationWhat is whooping cough. (pertussis)? Information and Prevention. Ocument dn
What is whooping cough Ocument dn (pertussis)? Information and Prevention IMPORTANT Pertussis (or whooping cough) is a highly contagious infection that can cause uncontrollable, violent coughing. If you
More informationHow Many Tdap Vaccines Are Given to San Diego County People?
Immunizations and Pregnancy Mark H. Sawyer, MD San Diego Immunization Partnership San Diego County Immunization Branch Objectives List vaccines that should be given either during pregnancy or immediately
More informationSimultaneous Immunization of Young
Vol. 40 Simultaneous Immunization of Young Children against Diphtheria, Tetanus, and Pertussis* Experience in a Northern Metropolitan Area LOUIS W. SAUER, PH.D., M.D., F.A.P.H.A., AND WINSTON H. TUCKER,
More informationPertussis (whooping cough) immunisation for pregnant women
Factsheet September 2012 Pertussis (whooping cough) immunisation for pregnant women Immunisation DEPARTMENT OF HEALTH Rheynn Slaynt The routine childhood immunisation programme has been very effective
More informationPertussis (Whooping Cough) http://www.cdc.gov/pertussis/index.html. Causes and Transmission. Causes. Transmission
Pertussis (Whooping Cough) http://www.cdc.gov/pertussis/index.html Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis.
More informationPertussis: halting the epidemic by protecting infants. 34 BPJ Issue 51
Pertussis: halting the epidemic by protecting infants 34 BPJ Issue 51 Infants who have not yet completed the National Immunisation Schedule and children who are not immunised, or only partially immunised
More informationALBERTA IMMUNIZATION POLICY GUIDELINES
ALBERTA IMMUNIZATION POLICY GUIDELINES Diphtheria, Tetanus, Pertussis, Polio and Hib Vaccines. Diphtheria-Tetanus-Acellular Pertussis-Polio-Haemophilus influenzae type b Conjugate Combined Vaccine (DTaP-IPV-
More informationPertussis and Pregnancy
Pertussis and Pregnancy Protect Your Patients From Pertussis (Whooping Cough) 1 Pertussis Video https://www.youtube.com/watch?v=f1g5woy5qce#a ction=share 2 1 Class Objectives By the end of this class the
More informationThe Reality Pertussis can be a serious illness, part icularly for babies and young children.
Sounds of Pertussis Pertussis, also known as whooping cough, is a poten tially deadly infection that can strike at any age, but is particularly dangerous for babies. The sounds of pertussis are like no
More informationDENMARK S CHILDHOOD VACCINATION PROGRAMME
DENMARK S CHILDHOOD VACCINATION PROGRAMME 2013 7th EDITION Denmark s childhood vaccination programme, 2012 7th edition 2013 by the Danish Health and Medicines Authority. All rights reserved. Danish Health
More informationThe Challenge of Whooping Cough:
The Challenge of Whooping Cough: Canada s Role in the Development of Pertussis Vaccines AUTHORS: Luis Barreto, M.B.B.S., M.D., M.H.Sc. Rob Van Exan, Ph.D. Christopher Rutty, Ph.D. CREATED THROUGH AN EDUCATIONAL
More informationWhooping Cough Vaccine for Pregnant Women
Whooping Cough Vaccine for Pregnant Women What is whooping cough (pertussis)? Whooping cough (also known as pertussis) is a highly contagious illness that can be life threatening. The disease is most serious
More informationTEMPORARY PROGRAMME PERTUSSIS VACCINATION FOR PREGNANT WOMEN
TEMPORARY PROGRAMME PERTUSSIS VACCINATION FOR PREGNANT WOMEN Richard Smithson Neil Irvine Maureen McCartney Consultant Health Protection October 2012 Pertussis/whooping cough The disease Whooping Cough
More informationTdaP-Booster (tee-dee-ay-pee boo-ster)
New Zealand Consumer Medicine Information TdaP-Booster (tee-dee-ay-pee boo-ster) Tetanus, diphtheria and pertussis (acellular mono-component) vaccine (adsorbed, reduced antigen content) CONSUMER MEDICINE
More informationBOOSTRIX PRODUCT INFORMATION
BOOSTRIX PRODUCT INFORMATION NAME OF THE MEDICINE Combined diphtheria-tetanus-acellular pertussis (dtpa) vaccine DESCRIPTION BOOSTRIX dtpa vaccine is a sterile suspension which contains diphtheria toxoid,
More informationPertussis: Resurgence, Prevention and Role of the Ob/Gyn
Pertussis: Resurgence, Prevention and Role of the Ob/Gyn Kimberly B. Fortner, MD Vanderbilt University Department OB/Gyn Division Maternal-Fetal Medicine Vanderbilt Vaccine Research Program Learning Objectives
More informationWhy Pertussis matters..
Why Pertussis matters.. Pertussis (Whooping cough) outbreaks continue to impact children & adults, both locally and across the US. Cases have been on the rise since the 1980 s. However, recent data on
More informationCalifornia Association for Medical Laboratory Technology
California Association for Medical Laboratory Technology Distance Learning Program WHAT S GOING ON WITH WHOOPING COUGH (PERTUSSIS)? Course # DL-997 by James I. Mangels, MA, CLS, MT(ASCP) Consultant Microbiology
More informationImmunization Healthcare Branch. Meningococcal Vaccination Program Questions and Answers. Prepared by
Immunization Healthcare Branch Meningococcal Vaccination Program Questions and Answers Prepared by Immunization Healthcare Branch (IHB), Defense Health Agency Last Updated: 27 Mar 06 www.vaccines.mil 877-GET-VACC
More informationUse of Diphtheria Toxoid-Tetanus Toxoid-Acellular Pertussis Vaccine as a Five-Dose Series
November 17, 2000 / Vol. 49 / No. RR-13 Inside: Continuing Medical Education for U.S. Physicians and Nurses Recommendations and Reports Use of Diphtheria Toxoid-Tetanus Toxoid-Acellular Pertussis Vaccine
More informationFrequently asked questions about whooping cough (pertussis)
Frequently asked questions about whooping cough (pertussis) About whooping cough What is whooping cough? Whooping cough is a highly contagious illness caused by bacteria. It mainly affects the respiratory
More informationTHE DANISH CHILDHOOD VACCINATION PROGRAMME
THE DANISH CHILDHOOD VACCINATION PROGRAMME 2015 CONTENTS Introduction 2 The Danish childhood vaccination programme 3 Why do we vaccinate children in Denmark? 4 The diseases 5 Diphtheria 5 Tetanus 5 Whooping
More informationDiphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Tripedia
268 3105097 AHFS Category: 80:08 Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Tripedia DTaP Page 1 of 13 DESCRIPTION Tripedia, Diphtheria and Tetanus Toxoids and Acellular Pertussis
More informationVaccination has proved effective in controlling several
ORIGINAL STUDIES Encephalopathy After Whole-Cell Pertussis or Measles Vaccination Lack of Evidence for a Causal Association in a Retrospective Case Control Study Paula Ray, MPH,* Jean Hayward, MD,* David
More informationUpdated Recommendations for Use of Tdap in Pregnant Women
From the Texas Department of State Health Services Immunization Branch The goal of the Vaccine Advisory is to disseminate, in a timely manner, practical information related to vaccines, vaccine-preventable
More informationHPA Guidelines for the Public Health Management of Pertussis
HPA Guidelines for the Public Health Management of Pertussis Author Gayatri Amirthalingam and the Pertussis Guidelines Group Pertussis Guidelines Group Gayatri Amirthalingam Consultant Epidemiologist,
More informationProtecting your baby against meningitis and septicaemia
Protecting your baby against meningitis and septicaemia caused by meningococcal B bacteria MenB vaccine now available! Information about the MenB vaccine and recommended paracetamol use mmunisation The
More informationUsing the Wisconsin Immunization Registry to Estimate Tdap Effectiveness for Preventing Pertussis
Using the Wisconsin Immunization Registry to Estimate Tdap Effectiveness for Preventing Pertussis Ashley Petit, MPH Wisconsin Department of Health Services AIRA Discovery Series October 27, 2014 1 Co-authors
More informationEpidemiology and Burden of Pertussis: Focus on Adolescent and Adult
Epidemiology and Burden of Pertussis: Focus on Adolescent and Adult Terapong Tantawichien Division of Infectious Diseases Department of Medicine, Chulalongkorn University And Queen Saovabha Memorial Institute
More informationPertussis has re-emerged as a
Continuing Nursing Education Objectives and posttest can be found on page 244. Pertussis: An Overview of the Disease, Immunization, and Trends for Nurses Regena Spratling, Myra Carmon Pertussis has re-emerged
More informationsafest place for your baby is in your arms...
Help protect your baby by helping to protect yourself. Photo: John Bentham Imagine a cough barreling through your infant s body at up to 100 mph. Help protect yourself and your family by getting an adult
More informationResource Document 6: Tetanus Immunization. I. Introduction
Resource Document 6: Tetanus Immunization I. Introduction Attention must be directed to adequate tetanus prophylaxis in the multiply injured patient, particularly if open-extremity trauma is present. The
More informationTdaPBooster. Tetanus, diphtheria and pertussis vaccination of children, adolescents and adults throughout life
TdaPBooster Tetanus, diphtheria and pertussis vaccination of children, adolescents and adults throughout life CONTENTS Statens Serum Institut vaccine production Pertussis in Denmark Pertussis vaccination
More informationINCREASED INCIDENCE OF PERTUSSIS (WHOOPING COUGH) IN MARATHON COUNTY
November 25, 2013 INCREASED INCIDENCE OF PERTUSSIS (WHOOPING COUGH) IN MARATHON COUNTY Since November 1, 2013, Marathon County Health Department has investigated 20 cases of laboratory confirmed pertussis
More informationAdult Vaccination Frequently Asked Questions: The Basics
The Basics Why should I get vaccinated? Vaccination is the best way to protect against infections that can make you sick and be passed on to those around you. 1 What kinds of side effects will I get from
More information4A. Types of Laboratory Tests Available and Specimens Required. Three main types of laboratory tests are used for diagnosing CHIK: virus
4. LABORATORY 4A. Types of Laboratory Tests Available and Specimens Required Three main types of laboratory tests are used for diagnosing CHIK: virus isolation, reverse transcriptase-polymerase chain reaction
More informationBE SURE. BE SAFE. VACCINATE.
DON T GET OR GIVE THE FLU THIS YEAR THANK YOU Vaccination is the only protection. www.immunisation.ie BE SURE. BE SAFE. VACCINATE. FLU VACCINE 2013-2014 Healthcare workers prevent the spread of flu and
More informationSCRIPTA MEDICA (BRNO) 81 (2): 97 104, June 2008. First Department of Paediatric Internal Medicine, Faculty of Medicine, Masaryk University, Brno
SCRIPTA MEDICA (BRNO) 81 (2): 97 104, June 2008 Is the level of IgG antibodies against pertussis toxin sufficient in vaccinated child population? Duřpektová M., Hrstková H. First Department of Paediatric
More informationFrom: Michael P. Schmitt, Ph. D. Laboratory of Respiratory and Special Pathogens, Division of Bacterial, Parasitic, and Allergenic Products, HFM-437
DEPARTMENT OF HEALTH & HUMAN SERVICES FDA, Center for Biologics Evaluation and Research MEMORANDUM Date: December 21,2007 From: Michael P. Schmitt, Ph. D. Laboratory of Respiratory and Special Pathogens,
More informationThis article is a CME/CE certified activity. To earn credit for this activity visit: http://www.medscape.org/viewarticle/750546
1 of 6 10/10/2011 7:17 PM This article is a CME/CE certified activity. To earn credit for this activity visit: http://www.medscape.org/viewarticle/750546 CME/CE Information CME/CE Released: 09/28/2011;
More informationVaccination against pertussis (Whooping cough) for pregnant women- 2014. Information for healthcare professionals
Vaccination against pertussis (Whooping cough) for pregnant women- 2014 Information for healthcare professionals About Public Health England Public Health England s mission is to protect and improve the
More informationTdap and MenC booster vaccines. Information for parents of children in First Year of second level school
Tdap and MenC booster vaccines Information for parents of children in First Year of second level school Tdap and MenC booster vaccines Information for parents of children in First Year of second level
More informationTransient Hypogammaglobulinemia of Infancy. Chapter 7
Transient Hypogammaglobulinemia of Infancy Chapter 7 An unborn baby makes no IgG (antibody) and only slowly starts producing it after birth. However, starting at about the sixth month of pregnancy, the
More informationFAQs on Influenza A (H1N1-2009) Vaccine
FAQs on Influenza A (H1N1-2009) Vaccine 1) What is Influenza A (H1N1-2009) (swine flu) 1? Influenza A (H1N1-2009), previously known as "swine flu", is a new strain of influenza virus that spreads from
More informationManaging pertussis outbreaks during humanitarian emergencies WHO Technical Note
WHO/HSE/EPR/DCE/2008.2 Managing pertussis outbreaks during humanitarian emergencies WHO Technical Note February 2008 World Health Organization 2008 All rights reserved. The designations employed and the
More informationNew Jersey Department of Health and Senior Services Communicable Disease Service Vaccine Preventable Disease Program (VPDP)
Pertussis (Whooping Cough) Control Guidelines Infectious Agent: Bordetella pertussis Clinical Manifestations: Fever is usually mild. Children and infants are most severely affected. Older adolescents and
More informationThe timing of vaccination with respect to anaesthesia and surgery. 1. Surgery following immunisation with inactivated vaccines
The timing of vaccination with respect to anaesthesia and surgery Main recommendations: 1. Surgery following immunisation with inactivated vaccines Delay surgery 48 hours post vaccination to avoid postvaccination
More informationAcellular vaccines for preventing whooping cough in children (Review)
Acellular vaccines for preventing whooping cough in children (Review) Zhang L, Prietsch SOM, Axelsson I, Halperin SA This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More information2 P age. Babies from Birth to Age 2
Contents Babies from Birth to Age 2... 2 Vaccines give parents the power... 2 Vaccines are recommended throughout our lives... 3 Talk to your doctor... 3 Vaccines are very safe... 3 Whooping Cough (Pertussis)...
More informationParent s Guide to CHILDHOOD IMMUNIZATIONS
Part One Vaccine-Preventable Part Three More Diseases About Vaccines and Childhood Vaccines 30 Parent s Guide to CHILDHOOD IMMUNIZATIONS Part 3: More About Vaccines How do vaccines work? To understand
More informationPertussis 1. DI PROTOCOL CHECKLIST
1. DI PROTOCOL CHECKLIST Enter available information into Merlin upon receipt of initial report Review background on disease, case definition and laboratory testing Contact provider to acquire medical
More informationPertussis vaccine in both children and adults. Gaston De Serres. MD, PhD Institut national de santé publique du Québec, and Université Laval, Quebec
Pertussis vaccine in both children and adults Gaston De Serres. MD, PhD Institut national de santé publique du Québec, and Université Laval, Quebec Disclosure I received research grants from GSK (hepatitis
More informationClinical presentation of pertussis varies by
AGE-SPECIFIC PRESENTATION AND BURDEN OF PERTUSSIS Sarah S. Long, MD* ABSTRACT Pertussis presentation often differs according to age group. Pertussis in very young infants can be difficult to recognize
More informationGlobal Vaccine Safety Essential Medicines & Health Products 20, Avenue Appia, CH-1211 Geneva 27 Switzerland s & Health Product INFORMATION SHEET OBSERVED RATE OF VACCINE REACTIONS DIPHTHERIA, PERTUSSIS,
More informationWhooping Cough. The Lungs Whooping cough is an infection of the lungs and breathing tubes, both of which are parts of the respiratory system.
Whooping Cough Introduction Whooping cough is a serious bacterial infection of the lungs and breathing tubes. It is also called pertussis. About 16 million cases of whooping cough happen worldwide each
More informationThe Immunization Office, located in the Student Health Center, is open year round to administer needed immunizations at a nominal fee.
Student Health Services 2815 Cates Avenue Raleigh, NC 27695-7304 919-515-2563 healthcenter.ncsu.edu The Immunization Record Form is designed to collect information about your current immunization status.
More informationSafety of HPV vaccination: A FIGO STATEMENT
Safety of HPV vaccination: A FIGO STATEMENT July, 2013 Human papillomavirus vaccines are used in many countries; globally, more than 175 million doses have been distributed. Extensive pre- and post-licensure
More informationWaning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children Nicola P. Klein, M.D., Ph.D., Joan Bartlett, M.P.H.,
More informationVaccinations and Spina Bifida and Hydrocephalus
shinecharity.org.uk info@shinecharity.org.uk 42 Park Road Peterborough PE1 2UQ 01733 555988 Vaccinations and Spina Bifida and Hydrocephalus Vaccines are made from parts of bacteria or viruses that cause
More informationPertussis (whooping cough) is a highly
MedicineToday 2011; 12(6): 40-48 PEER REVIEWED FEATURE POINTS: 2 CPD/2 PDP Whooping cough optimising prevention Key points Pertussis (whooping cough) is a highly infectious, vaccine-preventable disease.
More informationReturn of the Whoop! The Resurgence of Pertussis
Return of the Whoop! The Resurgence of Pertussis by Lynn B. DeSanto, Department of Science, Lackawanna College, Scranton, PA Whooping cough Doctors call the disease pertussis, after the bacterium Bordetella
More information